Editorial: Ocular hypotensive effects of autonomic drugs.
D000316:Adrenergic alpha-Agonists / Q000494:pharmacology; D000317:Adrenergic alpha-Antagonists / Q000494:pharmacology; D000318:Adrenergic beta-Agonists / Q000494:pharmacology; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D001082:Aqueous Humor / Q000378:metabolism; D001337:Autonomic Agents / Q000494:pharmacology*; D004837:Epinephrine / Q000494:pharmacology; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D007545:Isoproterenol / Q000494:pharmacology; D013948:Moxisylyte / Q000494:pharmacology; D009638:Norepinephrine / Q000494:pharmacology; D010277:Parasympathomimetics / Q000494:pharmacology; D010862:Pilocarpine / Q000494:pharmacology; D011433:Propranolol / Q000494:pharmacology
D000316:Adrenergic alpha-Agonists; D000317:Adrenergic alpha-Antagonists; D000318:Adrenergic beta-Agonists; D000319:Adrenergic beta-Antagonists; D001337:Autonomic Agents; D010277:Parasympathomimetics; D010862:Pilocarpine; D011433:Propranolol; D007545:Isoproterenol; D013948:Moxisylyte; D009638:Norepinephrine; D004837:Epinephrine